INTRODUCTION {#s1}
============

Osteosarcoma is the most common primary bony malignancies and first leading cause of sarcoma-related deaths in children and young adults. It mainly occurs in metaphyseal area of distal femur and proximal tibia. Osteosarcoma is highly aggressive tumor and most likely metastasizes to the lung \[[@R1]\]. Even though the survival rate has modestly increased over the last 2 decades by implicating radiotherapy and neo-adjuvant chemotherapy, five-year survival rate of metastatic osteosarcoma still remains in the range of 15% to 30%. For localized osteosarcoma which can be totally resectable, the five-year survival rate increases up to 70% \[[@R2]\]. Hence, excavating novel prognostic biomarkers of osteosarcoma is strongly needed to detect tumor at early stage. They will contribute to select better treatment options in earlier stages and predict the outcome more accurately.

MicroRNAs (miRNAs) are a class of small noncoding RNAs, which could interfere translation of many proteins after gene transcription \[[@R3]\]. Previous studies revealed that they are implicated on a variety of physiological processes including cellular differentiation, apoptosis, angiogenesis and cell proliferation \[[@R4]\]. Additionally, miRNAs play a pivotal role in tumorigenesis that can act either as tumor suppressor genes or oncogenes \[[@R3], [@R5]\]. Level of miRNAs expressed in several malignancies, including lung, kidney, liver, and cervical cancer were significantly different from that of normal tissue \[[@R6], [@R7]\]. Recent researches have demonstrated that various miRNAs are also altered in osteosarcoma tissue or blood sample \[[@R8]\]. These discoveries may indicate that miRNA could be potential prognostic biomarkers of osteosarcoma. Therefore, we meta-analyzed the prognostic value of altered miRNAs in patients with osteosarcoma.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

The electronic search identified 289 articles. Non-English language articles (n=3), non-human studies (n=13), conference abstracts (n=34), and 174 studies that did not meet the inclusion criteria based on their title and abstract were excluded. After reviewing the full text of 65 articles, 25 studies including 2,278 patients were eligible for inclusion in the study. The detailed procedure is shown in Figure [1](#F1){ref-type="fig"}. The studies included in this meta-analysis reported the prognostic value of 26 miRNAs in patients with osteosarcoma. Twenty-five studies assessing 26 miRNA expressions were included in the meta-analysis \[[@R9]--[@R33]\]. The prognostic value of miRNA expressions was assessed by analyzing overall survival (OS) in 2,278 patients, event free survival (EFS) in 1,569 patients. Visual inspection of the funnel plot suggested no evidence of publication bias (Figure [2B](#F2){ref-type="fig"} and [3B](#F3){ref-type="fig"}). The study characteristics are summarized in Table [1](#T1){ref-type="table"}.

![Flow chart](oncotarget-08-8726-g001){#F1}

![Forest plot A. and funnel plot B. for deaths of low expression of miRNA in osteosarcoma](oncotarget-08-8726-g002){#F2}

![Forest plot A. and funnel plot B. for events of low expression of miRNA in osteosarcoma](oncotarget-08-8726-g003){#F3}

###### Studies included in this meta-analysis

  Author                 Year of publication   Country       miRNA           No. of patients   Stage    Follow-up (months)   Endpoints   Expression associates with poor prognosis   Assay method   Sample
  ---------------------- --------------------- ------------- --------------- ----------------- -------- -------------------- ----------- ------------------------------------------- -------------- --------
  Cai H \[[@R10]\]       2013                  China         210             92                \-       105^a^               OS, EFS     High                                        RT-PCR         Tissue
  Li X \[[@R19]\]        2014                  China         17-92 cluster   117               I-III    55^a^                OS, EFS     High                                        RT-PCR         Tissue
  Tian Z \[[@R23]\]      2014                  China         128             100               \-       38.89^a^             OS, EFS     High                                        RT-PCR         Tissue
  Xu SH \[[@R27]\]       2014                  China         9               79                I-III    60^a^                OS          High                                        RT-PCR         Tissue
  Wang Z \[[@R26]\]      2014                  China         214             92                \-       107^a^               OS, EFS     High                                        RT-PCR         Tissue
  Cheng DD \[[@R14]\]    2015                  China         542-5p          40                \-       40                   EFS         High                                        RT-PCR         Tissue
  Yu LD \[[@R29]\]       2015                  China         130b            68                I-III    36                   OS, EFS     High                                        RT-PCR         Tissue
  Chen J \[[@R12]\]      2016                  China         130a            86                I-IV     60^a^                OS, EFS     High                                        RT-PCR         Tissue
  Zeng H \[[@R31]\]      2016                  China         199b-5p         98                I-IV     60^b^                OS, EFS     High                                        RT-PCR         Tissue
  Yang J \[[@R28]\]      2013                  China         132             166               II-III   105^a^               OS, EFS     Low                                         RT-PCR         Tissue
  Tang M \[[@R22]\]      2013                  China         145             166               II-III   100^a^               OS, EFS     Low                                         RT-PCR         Tissue
  Sarver AL \[[@R20]\]   2013                  USA           382             8                 \-       194^a^               OS, EFS     Low                                         RT-PCR         Tissue
  Ji F \[[@R18]\]        2013                  China         133a            92                I-III    60^a^                OS          Low                                         RT-PCR         Tissue
  Song QC \[[@R21]\]     2014                  China         26a             144               II-III   140^a^               OS, EFS     Low                                         RT-PCR         Tissue
  Cai H \[[@R11]\]       2014                  China         340             92                \-       100^a^               OS, EFS     Low                                         RT-PCR         Tissue
  Arabi L \[[@R9]\]      2014                  Switzerland   20a             57                \-       112                  OS          Low                                         RT-PCR         Tissue
  Arabi L \[[@R9]\]      2014                  Switzerland   92a             57                \-       112                  OS          Low                                         RT-PCR         Tissue
  Zhou J \[[@R33]\]      2015                  China         143             45                \-       36^c^                OS          Low                                         RT-PCR         Tissue
  Yuan J \[[@R30]\]      2015                  China         451             118               II-III   80^a^                OS, EFS     Low                                         RT-PCR         Tissue
  Wang W \[[@R25]\]      2015                  China         144             67                I-IV     80^a^                OS          Low                                         RT-PCR         Tissue
  Wang G \[[@R24]\]      2015                  China         22              52                I-IV     60c                  OS, EFS     Low                                         RT-PCR         Tissue
  Han K \[[@R17]\]       2015                  China         195             107               II-III   90^a^                OS          Low                                         RT-PCR         Tissue
  Han G \[[@R16]\]       2015                  China         124             105               II-III   80^a^                OS          Low                                         RT-PCR         Tissue
  Chen J \[[@R13]\]      2015                  China         449a            60                I-III    60^b^                OS          Low                                         RT-PCR         Tissue
  Zhao J \[[@R32]\]      2016                  China         99a             130               II-III   60^a^                OS, EFS     Low                                         RT-PCR         Tissue
  Geng S \[[@R15]\]      2016                  China         224             40                \-       60                   OS          Low                                         RT-PCR         Tissue

\- Follow-up; ^a^median, ^b^heterogeneity of logrank test, ^c^mean

\- OS, overall survival; EFS, event free survival; RT-PCR, reverse transcription polymerase chain reaction

miRNA expression and prognosis of osteosarcoma {#s2_2}
----------------------------------------------

To analyze the prognostic value of low expression of miRNA in osteosarcoma, forest plots with OS and EFS are depicted in Figure [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}. The pooled hazard ratio (HR) for deaths was 1.40 (95% confidence interval \[CI\] 1.01-1.94, *p*=0.04) with random-effects model (χ^2^=113.08, *p*\<0.00001, I^2^=79%), which means more deaths with lower expression of miRNA in osteosarcoma. However, the pooled HR for events did not show the significant value (HR 0.97, 0.63-1.48, *p*=0.87, χ^2^=72.65, *p*\<0.00001, I^2^=79%). Due to heterogeneity in pooled analysis of miRNA, we performed a subgroup analysis according to the expression level of miRNA. The HRs were calculated on the basis of low expression of miRNA, which means HR \> 1 and \< 1 implied poor and good prognosis for patients with low miRNA expression.

A. Worse prognosis with high miRNA expression {#s2_3}
---------------------------------------------

High expressions of miRNA210, 17-92 cluster, 128, 9, 214, 542-5p, 130b, 130a, 199b-5p were associated with poor prognosis of osteosarcoma patients, \[[@R10], [@R12], [@R14], [@R19], [@R23], [@R26], [@R27], [@R29], [@R31]\]. Eight studies were included to analyze OS with miRNA210, 17-92 cluster, 128, 9, 214, 130b, 130a, 199-5p in 732 patients \[[@R10], [@R12], [@R19], [@R23], [@R26], [@R27], [@R29], [@R31]\]. The HR ranged between 0.33 and 0.67 with a pooled HR for deaths of 0.45 (0.35-0.60, *p*\<0.00001) with low expression of miRNA, and the test for heterogeneity gave no significant results (χ^2^=2.47, *p*=0.93, I^2^=0%) (Table [2](#T2){ref-type="table"}). The EFS was analyzed with miRNA210, 17-92 cluster, 128, 214, 542-5p, 130b, 130a, 199b-5p based on 8 studies including 693 patients \[[@R10], [@R12], [@R14], [@R19], [@R23], [@R26], [@R29], [@R31]\]. The pooled HR of high miRNA for adverse events was 0.46 with a range from 0.30 to 0.71 (0.35-0.60, *p*\<0.00001), and the test for heterogeneity gave no significant results (χ^2^=4.37, *p*=0.74, I^2^=0%) (Table [2](#T2){ref-type="table"}). The forest plots for OS and EFS of high miRNA with worse prognosis are shown in Figure [4](#F4){ref-type="fig"}.

###### Subgroup analysis according to miRNA expression with prognosis

                                               No. of studies   miRNA                                                                                  HR     95% CI of HR   Heterogeneity I^2^ (%)   Model used
  -------------------------------------------- ---------------- -------------------------------------------------------------------------------------- ------ -------------- ------------------------ --------------
  Worse prognosis with high miRNA expression                                                                                                                                                          
  OS                                           8                210, 17-92, 128, 9, 214, 130b, 130a, 199b-5p                                           0.46   0.35-0.60      0                        Fixed effect
  EFS                                          8                210, 17-92, 128, 214, 542-5p, 130b, 130a, 199b-5p                                      0.46   0.35-0.60      0                        Fixed effect
  Worse prognosis with low miRNA expression                                                                                                                                                           
  OS                                           16               132, 145, 382, 133a, 26a, 340, 20a, 92a, 143, 451, 144, 22, 195, 124, 449a, 99a, 224   2.25   1.90-2.66      0                        Fixed effect
  EFS                                          8                132, 145, 382, 26a, 340, 451, 22, 99a                                                  2.05   1.67-5.18      0                        Fixed effect

\- HR, hazard ratio; OS, overall survival; EFS, event free survival

![Subgroup analysis: worse prognosis with high expression of miRNA; forest plots for deaths A. and events B. of low expression of miRNA in osteosarcoma](oncotarget-08-8726-g004){#F4}

B. Worse prognosis with low miRNA expression {#s2_4}
--------------------------------------------

Low expression of miRNA132, 145, 382, 133a, 26a, 340, 20a, 92a, 143, 451, 144, 22, 195, 124, 449a, 99a, 224 were found to be associated with a poor prognosis \[[@R9], [@R11], [@R13], [@R15]--[@R18], [@R20]--[@R22], [@R24], [@R25], [@R28], [@R30], [@R32], [@R33]\]. Sixteen studies analyzed OS with miRNA132, 145, 382, 133a, 26a, 340, 20a, 92a, 143, 451, 144, 22, 195, 124, 449a, 99a, 224 in 1,506 patients \[[@R9], [@R11], [@R13], [@R15]--[@R18], [@R20]--[@R22], [@R24], [@R25], [@R28], [@R30], [@R32], [@R33]\], and eight studies (miRNA132, 145, 382, 26a, 340, 451, 22, 99a) containing 876 patients that reported EFS were included to calculate the combined HRs \[[@R11], [@R20]--[@R22], [@R24], [@R28], [@R30], [@R32]\]. The HR for deaths ranged widely between 1.34 and 5.32 with a combined HR of 2.25 (1.90-2.66, *p*\<0.00001), and the pooled HR for events was 2.05 with a range from 1.05 to 7.01 (1.57-2.68, *p*\<0.00001). There was no significant heterogeneity (OS: χ^2^=10.58, p=0.83, I^2^=0%, EFS: χ^2^=6.71, *p*=0.46, I^2^=0%). The forest plots for OS and EFS of low miRNA with worse prognosis are shown in Figure [5](#F5){ref-type="fig"}.

![Subgroup analysis: worse prognosis with low expression of miRNA; forest plots for deaths A. and events B. of low expression of miRNA in osteosarcoma](oncotarget-08-8726-g005){#F5}

C. Pathway analysis of miRNAs {#s2_5}
-----------------------------

In a pathway analysis of miRNAs using mirPath v3.0 based on Tarbase, KEGG and GO, miRNA449a, 199-5p, 542-5p have target genes and signaling pathways, but others do not have known targets (Figure [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}, Table [3](#T3){ref-type="table"}) \[[@R34]\].

![The number of target genes of miRNA449a, 199-5p and 542-5p](oncotarget-08-8726-g006){#F6}

![Heatmap of pathway analysis of miRNA449a, 199-5p and 542-5p by KEGG pathway A. and GO categories B](oncotarget-08-8726-g007){#F7}

###### pathway analysis of miRNA449a, 199b-5p, 542-5p

  pathway analysis                                                                 *p*        no. of target genes   miRNA -449a   miRNA- 199b-5p   miRNA- 542-5p
  -------------------------------------------------------------------------------- ---------- --------------------- ------------- ---------------- ---------------
  **KEGG pathway**                                                                                                                                 
  Fatty acid biosynthesis                                                          0          3                     Y             N                Y
  Fatty acid metabolism                                                            0          3                     Y             N                Y
  ECM-receptor interaction                                                         0          10                    N             Y                Y
  Proteoglycans in cancer                                                          2.47E-07   15                    Y             Y                N
  Central carbon metabolism in cancer                                              1.58E-06   14                    Y             Y                N
  **GO Category**                                                                                                                                  
  molecular function                                                               0          789                   Y             Y                Y
  cellular protein modification process                                            0          155                   Y             Y                Y
  biological process                                                               0          780                   Y             Y                Y
  biosynthetic process                                                             0          255                   Y             Y                Y
  cellular nitrogen compound metabolic process                                     0          299                   Y             Y                Y
  ion binding                                                                      0          317                   Y             Y                Y
  organelle                                                                        0          596                   Y             Y                Y
  protein complex                                                                  1.33E-15   232                   Y             Y                Y
  cellular component                                                               5.00E-15   784                   Y             Y                Y
  enzyme binding                                                                   2.80E-13   103                   Y             Y                Y
  cellular component assembly                                                      5.09E-12   102                   Y             Y                Y
  catabolic process                                                                2.86E-10   126                   Y             Y                Y
  response to stress                                                               4.90E-08   136                   Y             Y                Y
  cytoskeletal protein binding                                                     1.68E-07   61                    Y             Y                Y
  small molecule metabolic process                                                 2.90E-07   130                   Y             Y                Y
  gene expression                                                                  0          70                    Y             Y                N
  symbiosis, encompassing mutualism through parasitism                             0          58                    Y             Y                N
  nucleoplasm                                                                      2.22E-16   97                    Y             Y                N
  cytosol                                                                          1.89E-15   174                   Y             Y                N
  viral process                                                                    1.43E-14   50                    Y             Y                N
  RNA binding                                                                      2.72E-12   122                   Y             Y                N
  cellular protein metabolic process                                               4.33E-12   43                    Y             Y                N
  protein binding transcription factor activity                                    6.72E-12   49                    Y             Y                N
  macromolecular complex assembly                                                  1.36E-08   64                    Y             Y                N
  membrane organization                                                            9.90E-08   45                    Y             Y                N
  cell junction organization                                                       5.04E-06   18                    Y             N                Y
  poly(A) RNA binding                                                              5.87E-06   103                   Y             Y                N
  protein complex assembly                                                         2.17E-05   52                    Y             Y                N
  transcription, DNA-templated                                                     9.55E-05   127                   Y             Y                N
  nucleobase-containing compound catabolic process                                 0.000168   53                    Y             Y                N
  enzyme regulator activity                                                        0.000207   51                    Y             Y                N
  transcription factor binding                                                     0.000255   43                    Y             Y                N
  generation of precursor metabolites and energy                                   0.0004     20                    Y             N                Y
  focal adhesion                                                                   0.000601   35                    Y             N                Y
  immune system process                                                            0.00162    81                    Y             Y                N
  activation of signaling protein activity involved in unfolded protein response   0.002297   9                     Y             Y                N
  platelet alpha granule lumen                                                     0.003495   7                     Y             Y                N

DISCUSSION {#s3}
==========

This study evaluated the prognostic value of miRNA in patients with osteosarcoma. As we described above, the combined HR of OS from the included studies was 1.40 (1.01-1.94, *p*=0.04), which provided that low expression of miRNAs was related with shorter OS in patients with osteosarcoma. However, the combined HR of EFS was not significant. Due to heterogeneity in pooled analysis of miRNA, we performed a subgroup analysis according to the expression level of miRNA. For a more detailed analysis, we performed a subgroup analysis according to miRNA expressions (high or low) related with poor prognosis. High expression of miRNA 210, 17-92 cluster, 128, 9, 214, 542-5p, 130b, 130a, and 199b-5p and low expression of miRNA 132, 145, 382, 133a, 26a, 340, 20a, 92a, 143, 451, 144, 22, 195, 124, 449a, 99a, 224 were associated with a poor prognosis of either deaths or events.

The possible role of miRNAs during osteosarcomagenesis is also investigated. Altered or aberrant expression of miRNA, its function during tumorigenesis, and potential target genes are summarized in Table [4](#T4){ref-type="table"}. Nine miRNAs (miRNA 210, 17-92 cluster, 128, 9, 214, 542-5p, 130b, 130a, and 199b-5p) whose expression level correlated with poor prognosis function as an oncogene in osteosarcoma. Of that, miRNA 210 contributes its action in tumor initiation. miRNA 17-92 cluster, 214, 130b have been reported as they progress early stage osteosarcoma into advanced stage. And miRNA 9, 130a are associated with metastasis. On the contrary, 17 miRNAs (132, 145, 382, 133a, 26a, 340, 20a, 92a, 143, 451, 144, 22, 195, 124, 449a, 99a, 224) function as a tumor suppressor gene, which expressed low level when they were related with worse outcome. Among these miRNAs, miRNA 382, 133a, 26a, 340, 143, 144, 195 have shown an anti-metastatic activity. Especially, miRNA 133a, 143 could be utilized as a future therapeutic target for lung metastasis. Moreover, miRNA 132, 145, 92a might act as a therapeutic standard for chemotherapy.

###### miRNAs with relative expression level associated with poor prognosis, their function and target or related gene

  miRNA                    Expression level associate with poor prognosis   Function                                                             Target or related gene
  ------------------------ ------------------------------------------------ -------------------------------------------------------------------- ------------------------
  miR-210\[[@R10]\]        high                                             Oncogene (Tumor Initiation)                                          N/D
  miR-17--92\[[@R19]\]     high                                             Oncogene (Tumor Progression)                                         N/D
  miR-128\[[@R23]\]        high                                             Oncogene                                                             Inhibits PTEN
  miR-9\[[@R27]\]          high                                             Oncogene Promote metastasis                                          N/D
  miR-214\[[@R26]\]        high                                             Oncogene (Tumor Progression)                                         N/D
  miR-542-5p \[[@R14]\]    high                                             Oncogene                                                             Inhibits HUWE1
  miR-130b \[[@R29]\]      high                                             Oncogene (Tumor Progression)                                         Inhibits PPARγ
  miR-130a \[[@R12]\]      high                                             Oncogene Promote metastasis                                          Inhibits PTEN
  miR-199b-5p \[[@R31]\]   high                                             Oncogene                                                             HES1
  miR-132 \[[@R28]\]       low                                              Discriminate good responders from poor responders                    N/D
  miR-145 \[[@R22]\]       low                                              Tumor suppressor Discriminate good responders from poor responders   N/D
  miR-382 \[[@R20]\]       low                                              Oncogene Suppress metastasis                                         Stabilize MYC
  miR-133a \[[@R18]\]      low                                              Tumor suppressor Suppress pulmonary metastasis                       Inhibits Bcl-xL, Mcl-1
  miR-26a \[[@R21]\]       low                                              Tumor suppressor Suppress metastasis and recurrence                  Inhibits EZH2
  miR-340 \[[@R11]\]       low                                              Tumor suppressor Suppress metastasis                                 N/D
  miR-20a \[[@R9]\]        low                                              Tumor suppressor                                                     Inhibits FAS
  miR-92a \[[@R9]\]        low                                              Discriminate ifosfamide responder                                    Inhibits FAS
  miR-143 \[[@R33]\]       low                                              Tumor suppressor Suppress pulmonary metastasis                       MMP-13 Bcl-2
  miR-451 \[[@R30]\]       low                                              Tumor suppressor                                                     N/D
  miR-144 \[[@R25]\]       low                                              Tumor suppressor Suppress metastasis                                 Inhibits ROCK1, ROCK2
  miR-22 \[[@R24]\]        low                                              Tumor suppressor                                                     Inhibits HMGB1
  miR-195 \[[@R17]\]       low                                              Suppress metastasis                                                  Inhibits CCND1
  miR-124 \[[@R16]\]       low                                              Tumor suppressor                                                     N/D
  miR-449a \[[@R13]\]      low                                              Tumor suppressor                                                     Inhibits Bcl-2
  miR-99a \[[@R32]\]       low                                              Tumor suppressor                                                     mTOR
  miR-224 \[[@R15]\]       Low                                              Tumor suppressor                                                     Rac1

\- N/D, not determined; PTEN, phosphatase and tensin homolog; HUWE1; PPARγ, peroxisome proliferator-activated receptor gamma; HES1, hes family bHLH transcription factor 1; MYC, v-myc avian myelocytomatosis viral oncogene homolog ; Bcl-xL, BCL2-like 1 isoform 1; Mcl-1, BCL2 family apoptosis regulator; EZH2, enhancer of zeste 2 polycomb repressive complex 2 subunit; FAS, tumor necrosis factor receptor superfamily member 6; MMP-13, matrix metallopeptidase 13; Bcl-2, B-cell lymphoma 2; ROCK, Rho-associated protein kinase; HMGB1, high mobility group box 1; CCND1, Cyclin D1; MTOR, mechanistic target of rapamycin; Rac1, Ras-related C3 botulinum toxin substrate 1

This is the first meta-analysis that evaluate the prognostic value of miRNAs in osteosarcoma. We demonstrated the association of the outcomes (OS, EFS) of osteosarcoma and level of miRNA expression. In addition, we measured HRs as the effectiveness endpoint in the current study. We did not measured the odds ratios or risk ratios whether these values represent only cross-sectional cumulative estimate and do not including the time factor \[[@R35]\]. Hence, HRs are most appropriate for our report which analyze time-to-event outcomes. The type of samples was homogenous. All of the samples which were experimented in included studies were obtained from tumor tissue of osteosarcoma patients. This might be increased reliability and decreased heterogeneity of our study. We excluded studies using serum or plasma because there were a few studies about serum or circulating miRNAs in patients with osteosarcoma \[[@R36], [@R37]\]. However, there are increasing interest in circulating miRNAs due to their comfortable accessibility by drawing patient\'s blood compared to miRNAs of tissue from operation and they could be easily repeated and monitored through.

From the pathway analysis, we found that several common targets and pathways of miRNA199b-5p, 449a and 542-5p, for example, fatty acid biosynthesis (target gene: Fatty Acid Synthase (FASN)) (Table [3](#T3){ref-type="table"}). FASN is known as a therapeutic target in the treatment of osteosarcoma metastasis \[[@R38]\]. Pathways related to other malignancies were found in this analysis, such as breast cancer, and prostate cancer \[[@R38]--[@R41]\]. The target genes of miRNAs in various cancers may overlap, which suggest that miRNAs could be promising therapeutic targets in cancer treatment.

In this study, we investigated the prognostic value of miRNA in patients with osteosarcoma using a meta-analysis approach. Finally, we concluded that decreased miRNA expression in tumor tissue is associated with worse outcome of patients with osteosarcoma. However, we should also pay attention to increased expression of several miRNAs in tumor tissue of osteosarcoma. Furthermore, prospective studies with a large sample size are warranted to clarify the prognostic role of miRNAs in osteosarcoma.

MATERIALS AND METHODS {#s4}
=====================

Data search and study election {#s4_1}
------------------------------

We performed a systematic search if MEDLINE (from inception to August 2016) and EMBASE (from inception to August 2016) for English-language publications using the keywords "osteosarcoma", "miRNA", "prognosis". All searches were limited to human studies. The inclusion criteria were studies of osteosarcoma that reported the results of miRNA expressions and survival data. Reviews, abstracts, and editorial materials were excluded. Two authors performed the searches and screening independently, and discrepancies were resolved by consensus.

Data extraction and statistical analysis {#s4_2}
----------------------------------------

Data were extracted from the publications independently by two reviewers, and the following information was recorded: first author, year of publication, country, miRNA expression analyzed, number of patients, staging, and end points. The primary outcome was OS, which was defined as the time from the initiation of therapy until death from any cause. The secondary end point was EFS. Data regarding disease-free survival (DFS), progression-free survival (PFS), recurrence-free survival (RFS) were obtained from the included studies, and were redefined as EFS, which was measured from the date of initiation of therapy to the date of recurrence or metastasis \[[@R42], [@R43]\].

The effects of miRNA expressions on survival were assessed using hazard ratios. Survival data were extracted following a methodology suggested previously \[[@R44]\]. A univariate HR estimate and 95% CIs were extracted directly from each study, if provided by the authors. Otherwise, *p* values of the log-rank tests, 95% confidence intervals, number of events, and numbers of patients at risk were extracted to estimate the HR indirectly. Survival rates calculated from Kaplan-Meier curves were read using Engauge Digitizer version 3.0 (<http://digitizer.sourceforge.net>) to reconstruct the HR estimate and its variance, assuming that patients were censored at a constant rate during follow-up. The HRs were calculated on the basis of low expression of miRNA, which means HR \> 1 and \< 1 implied poor and good prognosis for patients with low miRNA expression. Heterogeneity among studies was assessed using χ^2^ tests and I^2^ statistics, as described previously \[[@R45]\]. Funnel plots were used to assess publication bias \[[@R46]\]. *p* values \< 0.05 were considered to be statistically significant. The data from each study were analyzed using Review Manager (RevMan, Version 5.3 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). miRNA target genes and related pathways were predicted by DIANA-mirPath v3.0 (<http://www.microrna.gr/miRPathv3>) based on Tarbase, KEGG and GO \[[@R34]\] to interpret functional value of miRNAs.
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